Saraya – The New York Times published a report on the importance of strengthening prevention against seasonal flu. The work is on the discovery of a new vaccine that will protect the human from this virus completely; to reduce the annual mortality rates resulting from it. The report said in this report that this period of the year is the outbreak of seasonal influenza, which causes serious disease in the deaths of thousands of people around the world. Therefore, it is very important to receive seasonal vaccine in this period; to avoid infection. This vaccine may reduce the risk of influenza, but it does not protect the human completely from this disease, as the evolution of viruses from year to year directly affect the effectiveness of this vaccine. It may take months to develop a new and effective vaccine if a new strain of influenza viruses spreads, which means eliminating hundreds of thousands and possibly millions of human lives. The paper revealed that an international team of researchers was able to provide an overview of a better alternative to seasonal vaccine On Thursday. Through their research, researchers have been able to make an artificial antibody that protects mice from infection with dozens of strains of the influenza virus through an evolving combination of immunotherapy and gene therapy. This step is of great importance in the development of a type of influenza vaccine, Scientists have long been shielded from any virus that causes it. Michael Austerholm, director of the University of Minnesota Center for Infectious Diseases Policy and Research, praised the success of this step, which will provide a model for key studies on the subject. The pollen significantly reduces the number of deaths from the virus, A thousand deaths each year. The vaccine stimulates the body to form antibodies to protect against virus infection. In the meantime, these antibodies are looking for the target virus, making the task of penetrating these viruses into cells difficult. But unfortunately, each strain of these viruses has its own walk. Thus, effective antibodies against one strain of the influenza virus will not be effective in dealing with the rest of the strains. As a result, vaccine manufacturers should guess which strain of the flu virus will dominate next season and make vaccines accordingly. The paper said hope for a more effective vaccine emerged when scientists discovered that humans could produce rare antibodies against a group Different strains of influenza are sometimes known as 'broadly equivalent antibodies'. These antibodies target parts of the virus that are very similar to those found in another viral strain. Jost Kulkman, an engineer at Jansen Pharmaceuticals and co-author of the new study in the journal Science, said the antibody was unique. But it would be impossible to convince the human immune system to accept this artificial antibody, prompting researchers to work on an alternative strategy, which is to avoid the immune system completely. The newspaper that the researchers conducted a test on mice; to verify the effectiveness of this vaccine, where they initiated the outbreak of deadly strains Of influenza virus in the nose of mice. The new antibodies were able to encircle these viruses, preventing them from multiplying, and thus, these mice survived the deadly flu. In addition, this strategy was used to produce antibodies against other infectious diseases, similar to HIV. The success of this experiment with mice does not necessarily mean ensuring its success with humans. In the first place, the antibodies that were used to make this new type of lama were extracted instead of humans. The researchers also gave flu vaccines to the llamas, then collected antibodies found in the animal's blood, including some antibodies that proved effective against more than one viral strain. But the immune system is likely to reject these antibodies from the llamas. If so, they may attack the immune system, resulting in a serious reaction. In conclusion, the paper said that it is very important to conduct experiments on humans; to determine the effective dose, and to know how safe these new antibodies to humans. This task requires coordination between researchers, pharmaceutical companies and philanthropists, as well as adequate funding for research in this area.